Dr. Devalingam Mahalingam, MBBChBAO
Claim this profileNorthwestern University
Studies Uterine Tumors
Studies Cancer
18 reported clinical trials
54 drugs studied
Area of expertise
1Uterine Tumors
Stage IV
PTEN positive
PIK3CA positive
2Cancer
Stage IV
PTEN positive
PIK3CA positive
Affiliated Hospitals
Clinical Trials Devalingam Mahalingam, MBBChBAO is currently running
Pemetrexed
for Bladder Cancer
This phase II trial tests how well pemetrexed works in treating patients with urothelial bladder cancer and other solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) with mutations that result in a loss of function in the MLL4-protein/KMT2D-gene or UTX-protein/KDM6A-gene or MTAP enzyme. Loss of function due to a genetic mutation means a gene's activity may be reduced or eliminated. Mutations that result in a loss of function in the MLL4-protein or KMT2D-gene are found in 9.96% of all cancers including bladder carcinoma patients, esophageal squamous cell carcinoma and esophageal adenocarcinoma patients. In addition, mutations that result in a loss of function in the UTX-protein or KDM6A-gene are found in approximately 5% of all tumors, including bladder cancers, endometrial cancer, and esophagogastric cancer amongst many other tumor types. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Giving pemetrexed may increase response in patients with metastatic urothelial bladder cancer and other solid tumors with the loss of function in the MLL4-protein/KMT2D-gene or UTX-protein/KDM6A-gene or MTAP enzyme.
Recruiting1 award Phase 25 criteria
²¹²Pb-DOTAM-GRPR1
for Cancer
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Recruiting1 award Phase 16 criteria
More about Devalingam Mahalingam, MBBChBAO
Clinical Trial Related6 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Devalingam Mahalingam, MBBChBAO has experience with
- Hydroxychloroquine
- Fluorouracil
- Olaparib
- Sotorasib
- Binimetinib
- Palbociclib
Breakdown of trials Devalingam Mahalingam, MBBChBAO has run
Uterine Tumors
Solid Tumors
Thyroid Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Devalingam Mahalingam, MBBChBAO specialize in?
Devalingam Mahalingam, MBBChBAO focuses on Uterine Tumors and Cancer. In particular, much of their work with Uterine Tumors has involved Stage IV patients, or patients who are PTEN positive.
Is Devalingam Mahalingam, MBBChBAO currently recruiting for clinical trials?
Yes, Devalingam Mahalingam, MBBChBAO is currently recruiting for 9 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Devalingam Mahalingam, MBBChBAO has studied deeply?
Yes, Devalingam Mahalingam, MBBChBAO has studied treatments such as Hydroxychloroquine, Fluorouracil, Olaparib.
What is the best way to schedule an appointment with Devalingam Mahalingam, MBBChBAO?
Apply for one of the trials that Devalingam Mahalingam, MBBChBAO is conducting.
What is the office address of Devalingam Mahalingam, MBBChBAO?
The office of Devalingam Mahalingam, MBBChBAO is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.